Concord Medical Services
6 hedge funds and large institutions have $398K invested in Concord Medical Services in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
19,188% more capital invested
Capital invested by funds: $2.06K → $398K (+$396K)
100% more funds holding
Funds holding: 3 → 6 (+3)
2.47% more ownership
Funds ownership: 0% → 2.47% (+2.5%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$423K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
+$5.74K |
| 3 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$1.73K |
| 4 |
Morgan Stanley
New York
|
+$625 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$231 |
CCM Hedge Fund Activity: Q2 2025 in Review
6 of the 7,610 institutional investors tracked by Wall St. Rank reported a position in Concord Medical Services (CCM) for Q2 2025, worth a combined $398K — up 19,188% from $2.06K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CCM positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $423K. The largest seller was RhumbLine Advisers, cutting an estimated $231.
- 6 institutional investors held Concord Medical Services (CCM) as of Q2 2025, up from 3 in Q1 2025.
- Funds reported $398K of Concord Medical Services stock for Q2 2025, up 19,188% quarter-over-quarter.
- 3 funds opened new Concord Medical Services positions in Q2 2025 and 0 closed out, a net change of +3 holders.
- The largest Concord Medical Services buyer in Q2 2025 was UBS Group, an estimated $423K added.
- The largest Concord Medical Services seller in Q2 2025 was RhumbLine Advisers, an estimated $231 sold.
Based on aggregated 13F filings for Q2 2025.